Multicomponent meningococcal B vaccine (recombinant, adsorbed)

(Bexsero®)

Multicomponent meningococcal B vaccine (recombinant, adsorbed)

Drug updated on 10/23/2023

Dosage FormInjection (intramuscular: 0.5 ml (50 mcg))
Drug ClassVaccines
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for active immunization of individuals from 2 months through 25 years old against invasive disease caused by N. Meningitidis serogroup B strains.

Product Monograph / Prescribing Information

Document TitleYearSource
Bexsero (multicomponent meningococcal B vaccine (recombinant, adsorbed)) Prescribing Information.2022GlaxoSmithKline Inc., Mississauga, Ontario

Systematic Reviews / Meta-Analyses